China’s Anti-Monopoly Law, in force since Aug. 1, raises difficult questions for market players in the health care industry in China. One issue of particular importance is how to define the “relevant market” for medicinal products.
PharmAsia News
Insider Analysis from Sidley Austin LLP: Market Definition in Life Sciences Sector Under the Chinese Anti-Monopoly Law
September 22, 2008
Contacts
Stay Up To Date